Lotilibcin

Drug Profile

Lotilibcin

Alternative Names: JA 002; JA 002 - topical; WAP-8294A2

Latest Information Update: 30 Jun 2011

Price : $50

At a glance

  • Originator aRigen
  • Class Antibacterials; Depsipeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Methicillin-resistant Staphylococcus aureus infections
  • Preclinical Bacterial infections; Skin and soft tissue infections

Most Recent Events

  • 25 May 2009 Clinical development is ongoing in USA
  • 22 May 2009 WAP 8294A2 is no longer licensed to Janus Pharmaceuticals (now Topica Pharmaceuticals) in USA
  • 15 Apr 2005 Preclinical trials in Skin and soft tissue infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top